Latest / Stock Movers / SoHo and Dayforce Private Talks; Novo and Tonix See Pharma Jump
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio news.
- 0:08Speaker 2: The Stock Movers podcast, your roundup of companies making moves
- 0:13Speaker 2: in the stock market, harnessing the power of Bloomberg data.
- 0:17Speaker 3: Let's take a look at some of the stocks on
- 0:19Speaker 3: the move today. I'm Lis Matteo. We're joined by Bloomberg's
- 0:22Speaker 3: Valerie ty Tel now Valor. It looks like it's take
- 0:25Speaker 3: private Monday. Why is that? Yeah?
- 0:27Speaker 1: Look, we've had two, I guess reported take private deals.
- 0:32Speaker 1: One of them has been confirmed in that's soho House
- 0:34Speaker 1: going private at nine dollars a share. We're seeing the
- 0:37Speaker 1: likes of the share trade sixteen percent higher to eight
- 0:41Speaker 1: dollars in eighty eight cents in share, so very close
- 0:44Speaker 1: to that nine dollars a share mark. The deal implies
- 0:46Speaker 1: a total enterprise value for this private members club to
- 0:50Speaker 1: two point seven billion dollars. Investors and key shareholders have
- 0:54Speaker 1: actually been pushing for this move since late last year,
- 0:57Speaker 1: after the shares swamped after its IPO in twenty twenty one.
- 1:01Speaker 1: It actually ipo'd at fourteen dollars a share, so still
- 1:04Speaker 1: significantly under that IPO price back in twenty twenty one.
- 1:08Speaker 1: Apollo Global Management was central to the deal. According to
- 1:11Speaker 1: people familiar with the matter, as the Wall Street Journal
- 1:13Speaker 1: is reporting providing more than seven hundred million dollars in
- 1:16Speaker 1: equity and debt financing.
- 1:18Speaker 3: And the other one Toma Bravo.
- 1:20Speaker 1: Toma Bravo, this is the buyout firm is planning to
- 1:23Speaker 1: take software firm day Force private. This is a human
- 1:27Speaker 1: resource management software provider. We're seeing the likes of the
- 1:30Speaker 1: share jump nearly twenty nine percent in pre market trade.
- 1:33Speaker 1: The deal could be announced as soon as the coming weeks.
- 1:36Speaker 1: According to sources speaking to Bloomberg, day Force is down
- 1:39Speaker 1: about sixty percent since its twenty twenty one highs and
- 1:42Speaker 1: while the company has increased its revenue and become profitable,
- 1:46Speaker 1: the enterprise software market has been very difficult to navigate
- 1:50Speaker 1: since covid. It was valued at eight point four billion
- 1:53Speaker 1: dollars as of Friday's closed and is adding to that
- 1:55Speaker 1: pretty significantly. So far this morning, day Force up twenty
- 1:59Speaker 1: nine percent on a report of a take private by
- 2:02Speaker 1: Toma Bravo.
- 2:03Speaker 3: All right, so another trend, you're seeing FDA approvals. They're
- 2:06Speaker 3: pushing up gaids in some pharmaceutical companies.
- 2:08Speaker 1: Yeah, the big one being Nova Nordisk up three percent
- 2:10Speaker 1: in pre market trade on FDA approval for liver disease.
- 2:14Speaker 1: This would be using the company's blockbuster weight loss drug
- 2:17Speaker 1: we Goov, getting approval to treat a serious form of
- 2:21Speaker 1: liver disease. And the important thing about this is they
- 2:23Speaker 1: are now beating their rival Eli Lilly to the US
- 2:26Speaker 1: market to treat liver disease. Now using we go v
- 2:29Speaker 1: can help treat scar tissue on the liver, with the
- 2:31Speaker 1: drug reversing some liver damage. And after a tough start
- 2:34Speaker 1: to the year, this is a welcome upside surprise for
- 2:37Speaker 1: Novo Nordisk. This is the actually second positive catalyst for
- 2:41Speaker 1: the Danish pharma company this month. That comes after its
- 2:44Speaker 1: main rival, Eli Lilly's weight loss pill showed some weakness
- 2:48Speaker 1: around its efficacy in a clinical trial earlier. So it's
- 2:50Speaker 1: Novo Nordisk of three percent so far this morning.
- 2:52Speaker 3: All right, valoring, but I need your help on this one.
- 2:54Speaker 3: Is it Tonics Pharma?
- 2:55Speaker 1: Tonics Pharma explained Tonics pharmah, No, this is another catalyst
- 2:59Speaker 1: of an f approval for its fibromyalgia drug. This is
- 3:03Speaker 1: the move in the pre market this morning. It's up
- 3:06Speaker 1: twelve percent LISA following a trading halt head of this
- 3:09Speaker 1: announcement on Friday. The drug is expected to be available
- 3:12Speaker 1: in the fourth quarter, and the shares are liking this
- 3:14Speaker 1: news of the FDA approval. That's Tonics Pharma of twelve
- 3:17Speaker 1: percent so far in pre market.
- 3:20Speaker 2: The Stock Movers podcast from Bloomberg Radio. Check back with
- 3:24Speaker 2: us throughout the day for the latest roundup of companies
- 3:27Speaker 2: making news on Wall Street and for the latest market
- 3:30Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 3:34Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
- 3:38Speaker 2: the Bloomberg Business app.